Clinical Trials
10 trialsNCT03889912 2026-01-21
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Regeneron Pharmaceuticals
Phase 1 Completed
NCT04526899 2026-01-08
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
BioNTech SE
Phase 2 Completed
NCT04154943 2025-12-23
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals
Phase 2 Completed
NCT04157985 2025-12-11
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
Phase 3 Completed
NCT03836105 2025-10-15
CASE
Regeneron Pharmaceuticals
Completed
NCT05259696 2025-08-20
GLIMMER-01
Palleon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04339062 2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT03132636 2025-04-08
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Regeneron Pharmaceuticals
Phase 2 Completed
NCT02423863 2020-12-17
Poly-ICLC
Oncovir, Inc.
Phase 2 Completed
NCT03002376 2020-04-20
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
Regeneron Pharmaceuticals
Phase 1 Completed